BIOGEN INC (1BIIB.MI) Stock Price & Overview
BIT:1BIIB • US09062X1037
The current stock price of 1BIIB.MI is 144.45 EUR. Today 1BIIB.MI is down by -4.27%. In the past month the price increased by 5.9%.
1BIIB.MI Key Statistics
- Market Cap
- 21.191B
- P/E
- 10.13
- Fwd P/E
- 10.98
- EPS (TTM)
- 14.26
- Dividend Yield
- N/A
1BIIB.MI Stock Performance
1BIIB.MI Stock Chart
1BIIB.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 1BIIB.MI.
1BIIB.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1BIIB.MI. 1BIIB.MI has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
1BIIB.MI Earnings
On October 30, 2025 1BIIB.MI reported an EPS of 4.81 and a revenue of 2.53B. The company beat EPS expectations (21.48% surprise) and beat revenue expectations (6.23% surprise).
1BIIB.MI Forecast & Estimates
42 analysts have analysed 1BIIB.MI and the average price target is 163.34 EUR. This implies a price increase of 13.08% is expected in the next year compared to the current price of 144.45.
For the next year, analysts expect an EPS growth of -7.36% and a revenue growth 1.98% for 1BIIB.MI
1BIIB.MI Groups
Sector & Classification
1BIIB.MI Financial Highlights
Over the last trailing twelve months 1BIIB.MI reported a non-GAAP Earnings per Share(EPS) of 14.26. The EPS increased by 2.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.98% | ||
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| Debt/Equity | 0.35 |
1BIIB.MI Ownership
1BIIB.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 25.02 | 39.989B | ||
| ARGX | ARGENX SE | 24.87 | 39.878B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.004B | ||
| ABVX | ABIVAX SA | N/A | 7.544B | ||
| 2X1 | ABIVAX SA | N/A | 7.536B | ||
| GXE | GALAPAGOS NV | N/A | 1.874B | ||
| GLPG | GALAPAGOS NV | N/A | 1.871B | ||
| NANO | NANOBIOTIX | N/A | 1.275B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.05B | ||
| PHIL | PHILOGEN SPA | 16.85 | 605.268M | ||
| GNFT | GENFIT | N/A | 423.775M | ||
| VLA | VALNEVA SE | N/A | 378.219M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1BIIB.MI
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS US
Employees: 7605
Phone: 17814642000
BIOGEN INC / 1BIIB.MI FAQ
What does BIOGEN INC do?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
What is the stock price of BIOGEN INC today?
The current stock price of 1BIIB.MI is 144.45 EUR. The price decreased by -4.27% in the last trading session.
What is the dividend status of BIOGEN INC?
1BIIB.MI does not pay a dividend.
What is the ChartMill rating of BIOGEN INC stock?
1BIIB.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the market expecting 1BIIB stock to perform?
42 analysts have analysed 1BIIB.MI and the average price target is 163.34 EUR. This implies a price increase of 13.08% is expected in the next year compared to the current price of 144.45.
What is the Price/Earnings (PE) ratio of BIOGEN INC (1BIIB.MI)?
The PE ratio for BIOGEN INC (1BIIB.MI) is 10.13. This is based on the reported non-GAAP earnings per share of 14.26 and the current share price of 144.45 EUR.